Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

Using immuno-PET imaging to monitor kinetics of T cell-mediated inflammation and treatment efficiency in a humanized mouse model for GvHD.

Pektor S, Schlöder J, Klasen B, Bausbacher N, Wagner DC, Schreckenberger M, Grabbe S, Jonuleit H, Miederer M.

Eur J Nucl Med Mol Imaging. 2019 Aug 31. doi: 10.1007/s00259-019-04507-0. [Epub ahead of print]

PMID:
31471714
2.

Humanized mice in cutaneous leishmaniasis-Suitability analysis of human PBMC transfer into immunodeficient mice.

Fischer MR, Schermann AI, Twelkmeyer T, Lorenz B, Wegner J, Jonuleit H, von Stebut E.

Exp Dermatol. 2019 Sep;28(9):1087-1090. doi: 10.1111/exd.13999. Epub 2019 Aug 1.

PMID:
31260571
3.

Novel Concept of CD4-Mediated Activation of Regulatory T Cells for the Treatment of Graft-Versus-Host Disease.

Schlöder J, Berges C, Tuettenberg A, Jonuleit H.

Front Immunol. 2017 Nov 8;8:1495. doi: 10.3389/fimmu.2017.01495. eCollection 2017. Review.

4.

TCR signalling network organization at the immunological synapses of murine regulatory T cells.

van Ham M, Teich R, Philipsen L, Niemz J, Amsberg N, Wissing J, Nimtz M, Gröbe L, Kliche S, Thiel N, Klawonn F, Hubo M, Jonuleit H, Reichardt P, Müller AJ, Huehn J, Jänsch L.

Eur J Immunol. 2017 Dec;47(12):2043-2058. doi: 10.1002/eji.201747041. Epub 2017 Sep 12.

5.

Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.

Stergiou N, Glaffig M, Jonuleit H, Schmitt E, Kunz H.

ChemMedChem. 2017 Sep 7;12(17):1424-1428. doi: 10.1002/cmdc.201700387. Epub 2017 Aug 7.

PMID:
28675699
6.

Dendritic Mesoporous Silica Nanoparticles for pH-Stimuli-Responsive Drug Delivery of TNF-Alpha.

Kienzle A, Kurch S, Schlöder J, Berges C, Ose R, Schupp J, Tuettenberg A, Weiss H, Schultze J, Winzen S, Schinnerer M, Koynov K, Mezger M, Haass NK, Tremel W, Jonuleit H.

Adv Healthc Mater. 2017 Jul;6(13). doi: 10.1002/adhm.201700012. Epub 2017 May 29.

PMID:
28557249
7.

Bioconjugation of Small Molecules to RNA Impedes Its Recognition by Toll-Like Receptor 7.

Hellmuth I, Freund I, Schlöder J, Seidu-Larry S, Thüring K, Slama K, Langhanki J, Kaloyanova S, Eigenbrod T, Krumb M, Röhm S, Peneva K, Opatz T, Jonuleit H, Dalpke AH, Helm M.

Front Immunol. 2017 Mar 24;8:312. doi: 10.3389/fimmu.2017.00312. eCollection 2017.

8.

Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells.

Schlöder J, Berges C, Luessi F, Jonuleit H.

Int J Mol Sci. 2017 Jan 28;18(2). pii: E271. doi: 10.3390/ijms18020271.

9.

Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy.

Jonuleit H, Bopp T, Becker C.

Nanomedicine (Lond). 2016 Oct;11(20):2699-2709. Epub 2016 Sep 21. Review.

PMID:
27654070
10.

Pillars Article: Induction of Tolerance by IL-10-Treated Dendritic Cells. J. Immunol. 1997. 159: 4772-4780.

Steinbrink K, Wölfl M, Jonuleit H, Knop J, Enk AH.

J Immunol. 2016 Sep 1;197(5):1547-55. No abstract available.

11.

A key role of GARP in the immune suppressive tumor microenvironment.

Hahn SA, Neuhoff A, Landsberg J, Schupp J, Eberts D, Leukel P, Bros M, Weilbaecher M, Schuppan D, Grabbe S, Tueting T, Lennerz V, Sommer C, Jonuleit H, Tuettenberg A.

Oncotarget. 2016 Jul 12;7(28):42996-43009. doi: 10.18632/oncotarget.9598.

12.

Editorial: Current Concepts of Cellular and Biological Drugs to Modulate Regulatory T Cell Activity in the Clinic.

Jonuleit H, Bopp T.

Front Immunol. 2016 Apr 14;7:141. doi: 10.3389/fimmu.2016.00141. eCollection 2016. No abstract available.

13.

Kinome Profiling of Regulatory T Cells: A Closer Look into a Complex Intracellular Network.

Tuettenberg A, Hahn SA, Mazur J, Gerhold-Ay A, Scholma J, Marg I, Ulges A, Satoh K, Bopp T, Joore J, Jonuleit H.

PLoS One. 2016 Feb 16;11(2):e0149193. doi: 10.1371/journal.pone.0149193. eCollection 2016.

14.

Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells.

Trinschek B, Luessi F, Gross CC, Wiendl H, Jonuleit H.

Int J Mol Sci. 2015 Jul 17;16(7):16330-46. doi: 10.3390/ijms160716330.

15.

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.

Luessi F, Kraus S, Trinschek B, Lerch S, Ploen R, Paterka M, Roberg T, Poisa-Beiro L, Klotz L, Wiendl H, Bopp T, Jonuleit H, Jolivel V, Zipp F, Witsch E.

Mult Scler. 2015 Dec;21(14):1811-22. doi: 10.1177/1352458515574895. Epub 2015 Mar 2.

PMID:
25732840
16.

Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo.

Ulges A, Klein M, Reuter S, Gerlitzki B, Hoffmann M, Grebe N, Staudt V, Stergiou N, Bohn T, Brühl TJ, Muth S, Yurugi H, Rajalingam K, Bellinghausen I, Tuettenberg A, Hahn S, Reißig S, Haben I, Zipp F, Waisman A, Probst HC, Beilhack A, Buchou T, Filhol-Cochet O, Boldyreff B, Breloer M, Jonuleit H, Schild H, Schmitt E, Bopp T.

Nat Immunol. 2015 Mar;16(3):267-75. doi: 10.1038/ni.3083. Epub 2015 Jan 19.

PMID:
25599562
17.

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway.

Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, Wallmeier H, Haas J, Wildemann B, Fritz B, Jonuleit H, Kubach J, Dingermann T, Radeke HH, Osterroth F, Uherek C, Czeloth N, Schüttrumpf J.

Immunol Cell Biol. 2015 Apr;93(4):396-405. doi: 10.1038/icb.2014.102. Epub 2014 Dec 16.

18.

IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.

Kubach J, Hubo M, Amendt C, Stroh C, Jonuleit H.

Int J Cancer. 2015 Feb 15;136(4):821-30. doi: 10.1002/ijc.29037. Epub 2014 Jun 26.

19.

Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.

Kraus SH, Luessi F, Trinschek B, Lerch S, Hubo M, Poisa-Beiro L, Paterka M, Jonuleit H, Zipp F, Jolivel V.

Int Immunopharmacol. 2014 Feb;18(2):347-57. doi: 10.1016/j.intimp.2013.11.027. Epub 2013 Dec 5.

PMID:
24316255
20.

Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis.

Trinschek B, Luessi F, Haas J, Wildemann B, Zipp F, Wiendl H, Becker C, Jonuleit H.

PLoS One. 2013 Oct 14;8(10):e77634. doi: 10.1371/journal.pone.0077634. eCollection 2013. Erratum in: PLoS One. 2013;8(11). doi: 10.1371/annotation/0e76c09e-75b2-493a-90fd-cda3187a0888. Lüssi, Felix [corrected to Luessi, Felix].

Supplemental Content

Loading ...
Support Center